| Miriam Castro, | |
|
Carretera #2 402, Anasco, PR 00610-0000 | |
| (787) 826-1093 | |
| Not Available |
| Full Name | Miriam Castro |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | Carretera #2 402, Anasco, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639463557 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 4966 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miriam Castro, Po Box 588, San Sebastian, PR 00685-0588 Ph: () - | Miriam Castro, Carretera #2 402, Anasco, PR 00610-0000 Ph: (787) 826-1093 |
News Archive
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.
Take a quantum dot, add a coating of poly(ethylene glycol) (PEG), and attach a homing peptide and a piece of small interfering RNA (siRNA), and the result is a targeted nanoparticle that can stop the production of a specific protein by a targeted cell.
The Icahn School of Medicine at Mount Sinai joins a top-flight network of 25 regional stroke centers announced by the National Institute of Health that will focus on prevention, treatment, and recovery from stroke.
CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.
Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.
› Verified 5 days ago
Dr. Maryelis Gonzalez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Carr 402, Anasco, PR 00610 Phone: 787-229-1150 Fax: 787-229-1160 | |
Eydia S Barreto Perez, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle 65 De Infanteria #68, Anasco, PR 00610 Phone: 787-826-2390 | |
Cristina Irais Gonzalez Rivera, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carr. 402 Km 1.8, Bo. Marias, Zona Industrial, Anasco, PR 00610 Phone: 787-229-1515 Fax: 787-229-1516 | |
Dr. Randy Omar Rivera Aviles, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 17 Calle San Antonio, Anasco, PR 00610 Phone: 787-826-4400 | |
Mrs. Dorothy E Rosario Hoke, RPHA PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 402 Road Km 2, Centro Comercial Feliberti, Anasco, PR 00610 Phone: 787-826-8888 Fax: 787-826-7777 | |
Lizeyda Nieves, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Pr 2 & Pr 402, Anasco, PR 00610 Phone: 787-826-1092 Fax: 787-826-2333 | |
Dr. Lesley Arcelay Feliciano, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carr 402 Km 2.9 Bo Quebrada Larga, Anasco, PR 00610 Phone: 787-826-8888 |